Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||Olaparib + THZ1||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Lynparza (olaparib) treatment combined with THZ1 resulted in a synergistic effect in homologous recombination-proficient triple-receptor negative breast cancer cells, demonstrating decreased cell survival and anchorage-independent growth in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 32668240).||32668240|